Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Immunoconjugates"" wg kryterium: Temat


Tytuł:
Top advances of the year: Ovarian cancer.
Autorzy:
Lumish MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kohn EC; National Cancer Institute, Bethesda, Maryland, USA.
Tew WP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Mar 15; Vol. 130 (6), pp. 837-845. Date of Electronic Publication: 2023 Dec 15.
Typ publikacji:
Review; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Ovarian Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/therapeutic use
Female ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Carcinoma, Ovarian Epithelial/drug therapy ; Neoplasm Recurrence, Local/pathology
Czasopismo naukowe
Tytuł:
Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Autorzy:
Nakazawa Y; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan. .
Miyano M; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Tsukamoto S; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Kogai H; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Yamamoto A; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Iso K; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Inoue S; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Yamane Y; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Yabe Y; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Umihara H; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Taguchi J; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Akagi T; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.; KAN Research Institute, Inc., Kobe, Japan.
Yamaguchi A; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Koga M; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Toshimitsu K; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.
Hirayama T; KAN Research Institute, Inc., Kobe, Japan.
Mukai Y; KAN Research Institute, Inc., Kobe, Japan.
Machinaga A; Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.; KAN Research Institute, Inc., Kobe, Japan.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Mar 11; Vol. 15 (1), pp. 2192. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Pancreatic Neoplasms*/genetics
Carcinoma, Pancreatic Ductal*/genetics
Humans ; Mice ; Animals ; Cell Line, Tumor ; Tumor Microenvironment ; Antigens, CD ; Cell Adhesion Molecules ; GPI-Linked Proteins
Czasopismo naukowe
Tytuł:
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Autorzy:
Liu H; Department of General Surgery, First Affiliated Hospital, Gannan Medical University, Ganzhou, 341000, China.; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.
Zhou D; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China.
Liu D; Department of General Surgery, First Affiliated Hospital, Gannan Medical University, Ganzhou, 341000, China.; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.
Xu X; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China.
Zhang K; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China.
Hu R; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China.
Xiong P; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China.
Wang C; Department of General Surgery, First Affiliated Hospital, Gannan Medical University, Ganzhou, 341000, China.; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China.
Zeng X; Department of General Surgery, First Affiliated Hospital, Gannan Medical University, Ganzhou, 341000, China. .; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China. .
Wang L; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China. .; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China. .
Zhang S; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University, Ganzhou, 341000, China. .; School of Basic Medicine, Gannan Medical University, Ganzhou, 341000, China. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2024 Mar 05; Vol. 15 (3), pp. 187. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Humans ; Phosphatidylinositol 3-Kinases ; Antibodies ; Gemcitabine
Czasopismo naukowe
Tytuł:
Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment.
Autorzy:
Wang T; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Li M; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Wei R; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Wang X; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Lin Z; Shanghai Wei Er Lab, Shanghai 201799, China.; Shandong University of Traditional Chinese Medicine, No.4655, University Road, Jinan, Shandong 250355, China.
Chen J; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Wu X; Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China.; Shanghai Wei Er Lab, Shanghai 201799, China.
Pokaż więcej
Źródło:
Molecular pharmaceutics [Mol Pharm] 2024 Mar 04; Vol. 21 (3), pp. 1038-1055. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Immunoconjugates*/chemistry
Neoplasms*/drug therapy
Antigens
Czasopismo naukowe
Tytuł:
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.
Autorzy:
Li M; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.
Zhao X; The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, China Pharmaceutical University, Nanjing, People's Republic of China.
Yu C; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.
Wang L; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China. .
Pokaż więcej
Źródło:
Pharmaceutical research [Pharm Res] 2024 Mar; Vol. 41 (3), pp. 419-440. Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunoconjugates*/therapeutic use
Immunoconjugates*/chemistry
Humans ; Antibodies/therapeutic use ; Drug Industry ; Commerce
Czasopismo naukowe
Tytuł:
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Autorzy:
Santi DV; Prolynx, Inc., 135 Mississippi Street, San Francisco, CA, 94107, USA. .; Pharmaceutical Chemistry, UCSF, San Francisco, CA, USA. .
Ashley GW; Prolynx, Inc., 135 Mississippi Street, San Francisco, CA, 94107, USA.
Cabel L; Medical Oncology, Institut Curie, Paris, France.
Bidard FC; Medical Oncology, Institut Curie, Paris, France.; UVSQ/Paris Saclay University, Paris, France.
Pokaż więcej
Źródło:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2024 Mar; Vol. 38 (2), pp. 171-176. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Prodrugs*/pharmacology
Prodrugs*/therapeutic use
Neoplasms*/drug therapy
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Antibodies, Monoclonal, Humanized*
Camptothecin/*analogs & derivatives
Humans ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Antigens, Neoplasm
Czasopismo naukowe
Tytuł:
Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.
Autorzy:
Bernardim B; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Conde J; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
Hakala T; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Becher JB; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Canzano M; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Vasco AV; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Knowles TPJ; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.
Cameron J; Albumedix Ltd, Mabel Street, Nottingham NG2 3ED, United Kingdom.
Bernardes GJL; Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, United Kingdom.; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
Pokaż więcej
Źródło:
Bioconjugate chemistry [Bioconjug Chem] 2024 Feb 21; Vol. 35 (2), pp. 132-139. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Immunoconjugates*/metabolism
Neoplasms*/drug therapy
Humans ; Infant, Newborn ; Albumins/metabolism ; Cathepsin B/metabolism ; Cell Line, Tumor ; Peptide Hydrolases ; Tissue Distribution
Czasopismo naukowe
Tytuł:
Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics.
Autorzy:
Dean TT
Jelú-Reyes J
Allen AC
Moore TW
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 08; Vol. 67 (3), pp. 1641-1661. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Immunoconjugates*/chemistry
Antigens ; Peptides/pharmacology ; Peptides/therapeutic use ; Peptides/chemistry ; Drug Design
Czasopismo naukowe
Tytuł:
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Autorzy:
Dri A; Department of Medicine, University of Udine, Udine, Italy; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano (PN), Italy. Electronic address: .
Arpino G; Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy.
Bianchini G; Department of Medical Oncology, San Raffaele Hospital, Milan, Italy; School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
Curigliano G; Division of New Drugs and Early Drug Development, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
De Laurentiis M; Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Del Mastro L; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, Clinical Unit of Medical Oncology, IRCCS Hospital Policlinico San Martino, Genova, Italy.
Fabi A; Precision Medicine in Breast Cancer Unit, Department of Woman and Child Health and Public Health, IRCCS, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
Generali D; Department of Medicine, Surgery and Health Sciences, Cattinara Hospital, University of Trieste, Trieste, Italy; Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy.
Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy, Ospedale Maggiore della Caritá, Novara, Italy.
Guarneri V; Medical Oncology 2, Veneto Institute of Oncology (IOV), IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Santini D; Oncologia Medica A, Policlinico Umberto 1, La Sapienza Università Di Roma, Rome, Italy.
Simoncini E; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Zamagni C; Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Puglisi F; Department of Medicine, University of Udine, Udine, Italy; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano (PN), Italy.
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102672. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Breast Neoplasms*/drug therapy
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Humans ; Female ; Irinotecan ; Camptothecin/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antigens, Surface/therapeutic use
Czasopismo naukowe
Tytuł:
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Autorzy:
Lewis GD; Discovery Oncology, Genentech, South San Francisco, CA, USA. .
Li G; Discovery Oncology, Genentech, South San Francisco, CA, USA.
Guo J; Discovery Oncology, Genentech, South San Francisco, CA, USA.
Yu SF; Translational Oncology, Genentech, South San Francisco, CA, USA.
Fields CT; US Medical Affairs, Genentech, South San Francisco, CA, USA.
Lee G; Translational Oncology, Genentech, South San Francisco, CA, USA.
Zhang D; DMPK, Genentech, South San Francisco, CA, USA.
Dragovich PS; Discovery Chemistry, Genentech, South San Francisco, CA, USA.
Pillow T; Discovery Chemistry, Genentech, South San Francisco, CA, USA.
Wei B; Computational Chemistry, Genentech, South San Francisco, CA, USA.
Sadowsky J; Protein Chemistry, Genentech, South San Francisco, CA, USA.; Carmot Therapeutics, Berkeley, CA, USA.
Leipold D; Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, CA, USA.
Wilson T; Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
Kamath A; Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, CA, USA.
Mamounas M; Project Team Leadership, Oncology, Genentech, South San Francisco, CA, USA.
Lee MV; Bioanalytical Sciences, Genentech, South San Francisco, CA, USA.
Saad O; Bioanalytical Sciences, Genentech, South San Francisco, CA, USA.
Choeurng V; Data Sciences, Genentech, South San Francisco, CA, USA.
Ungewickell A; Early Clinical Development, Oncology, Genentech, South San Francisco, CA, USA.
Monemi S; Early Clinical Development, Oncology, Genentech, South San Francisco, CA, USA.
Crocker L; Translational Oncology, Genentech, South San Francisco, CA, USA.
Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
Modi S; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
LoRusso P; Yale Cancer Center, Yale University, New Haven, CT, USA.
Krop I; Yale Cancer Center, Yale University, New Haven, CT, USA.
Schutten MM; Safety Assessment Pathology, Genentech, South San Francisco, CA, USA.; SeaGen, South San Francisco, CA, USA.
Commerford R; Early Clinical Development, Oncology, Genentech, South San Francisco, CA, USA.; Gilead Sciences, Foster City, CA, USA.
Sliwkowski MX; Molecular Oncology, Genentech, South San Francisco, CA, USA.
Cho E; Early Clinical Development, Oncology, Genentech, South San Francisco, CA, USA.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Jan 11; Vol. 15 (1), pp. 466. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Benzodiazepines*
Antibodies, Monoclonal, Humanized*
Humans ; Animals ; Female ; Macaca fascicularis/genetics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use ; DNA
Czasopismo naukowe
Tytuł:
ADCdb: the database of antibody-drug conjugates.
Autorzy:
Shen L; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Sun X; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China.
Chen Z; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Guo Y; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Shen Z; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Song Y; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Xin W; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.
Ding H; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.
Ma X; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.
Xu W; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Zhou W; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.
Che J; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Tan L; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.
Chen L; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.
Chen S; School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Dong X; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Fang L; Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.; School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhu F; College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2024 Jan 05; Vol. 52 (D1), pp. D1097-D1109.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Databases, Pharmaceutical*
Animals ; Humans ; Antibodies/therapeutic use ; Antineoplastic Agents/therapeutic use ; Biological Products ; Cell Line, Tumor ; Disease Models, Animal
Czasopismo naukowe
Tytuł:
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET.
Autorzy:
Evers A; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Krah S; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Demir D; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Gaa R; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Elter D; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Schroeter C; ADC and Targeted Therapeutics, Merck Healthcare KGaA, Darmstadt, Germany.
Zielonka S; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Rasche N; ADC and Targeted Therapeutics, Merck Healthcare KGaA, Darmstadt, Germany.
Dotterweich J; Research Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Knuehl C; Research Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Doerner A; Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Pokaż więcej
Źródło:
MAbs [MAbs] 2024 Jan-Dec; Vol. 16 (1), pp. 2302386. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/genetics
Immunoconjugates*/chemistry
Antineoplastic Agents*
Animals ; Molecular Docking Simulation ; Cell Line, Tumor ; Hydrophobic and Hydrophilic Interactions ; Mammals
Czasopismo naukowe
Tytuł:
Development of antibody-drug conjugates in cancer: Overview and prospects.
Autorzy:
Ruan DY; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Wu HX; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Meng Q; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Xu RH; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Pokaż więcej
Źródło:
Cancer communications (London, England) [Cancer Commun (Lond)] 2024 Jan; Vol. 44 (1), pp. 3-22. Date of Electronic Publication: 2023 Dec 30.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunoconjugates*/therapeutic use
Immunoconjugates*/chemistry
Immunoconjugates*/pharmacology
Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; China
Czasopismo naukowe
Tytuł:
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
Autorzy:
Ali A; Department of Breast Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Institute, 9500 Euclid Ave / CA-060, Cleveland, OH, 44195, USA. .
Graff SL; Division of Hematology & Medical Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, 593 Eddy St., Providence, RI, 02903, USA.
Pokaż więcej
Źródło:
Current oncology reports [Curr Oncol Rep] 2024 Jan; Vol. 26 (1), pp. 1-9. Date of Electronic Publication: 2023 Dec 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Breast Neoplasms*/pathology
Camptothecin/*analogs & derivatives
Humans ; Female ; Receptor, ErbB-2/metabolism ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Camptothecin/pharmacology ; Camptothecin/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use
Czasopismo naukowe
Tytuł:
Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates.
Autorzy:
Chazeau E; ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, Dijon 21078, France.; Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, Paris 75000, France.; LIIC, EA7269, Université de Bourgogne, Dijon 21000, France.
Fabre C; Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble 38000, France.; Grenoble Alpes University Hospital (CHUGA), Grenoble 38043, France.
Privat M; ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, Dijon 21078, France.
Godard A; ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, Dijon 21078, France.
Racoeur C; Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, Paris 75000, France.; LIIC, EA7269, Université de Bourgogne, Dijon 21000, France.
Bodio E; ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, Dijon 21078, France.
Busser B; Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble 38000, France.; Grenoble Alpes University Hospital (CHUGA), Grenoble 38043, France.; Institut Universitaire de France (IUF), Paris 75005, France.
Wegner KD; Division Biophotonics, Federal Institute for Materials Research and Testing (BAM), 12489 Berlin, Germany.
Sancey L; Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble 38000, France.
Paul C; Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, Paris 75000, France.; LIIC, EA7269, Université de Bourgogne, Dijon 21000, France.
Goze C; ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, Dijon 21078, France.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Mar 14; Vol. 67 (5), pp. 3679-3691. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Water*
Immunoconjugates*
Trastuzumab ; Boron Compounds ; Fluorescent Dyes
Czasopismo naukowe
Tytuł:
Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling.
Autorzy:
Sankar AP; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Cho HM; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Shin SU; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Sneh T; The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Ramakrishnan S; Sylvester Comprehensive Cancer Center, Miami, Florida.; Dewitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Elledge C; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Zhang Y; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Das R; Synergys Biotherapeutics, Inc., Alamo, California.
Gil-Henn H; The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Rosenblatt JD; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, Miami, Florida.
Pokaż więcej
Źródło:
Cancer research communications [Cancer Res Commun] 2024 Mar 11; Vol. 4 (3), pp. 738-756.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Immunoconjugates*/metabolism
Humans ; Integrins/metabolism ; Cell Line, Tumor ; Endostatins/metabolism ; Integrin alpha5beta1/metabolism ; ErbB Receptors/metabolism ; STAT3 Transcription Factor/metabolism
Czasopismo naukowe
Tytuł:
Site-Selective Protein Conjugation by a Multicomponent Ugi Reaction.
Autorzy:
Koutsopetras I; Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
Vaur V; Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
Benazza R; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Diemer H; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Sornay C; Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
Ersoy Y; Lehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354, Freising, Germany.
Rochet L; Department of Chemistry, University College London, London, UK.
Longo C; Lehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354, Freising, Germany.
Hernandez-Alba O; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Erb S; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Detappe A; Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Skerra A; Lehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354, Freising, Germany.
Wagner A; Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
Cianferani S; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Chaubet G; Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2024 Mar 07; Vol. 30 (14), pp. e202303242. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Proteins*/chemistry
Immunoconjugates*
Lysine/chemistry ; Amino Acids ; Antibodies ; Chemical Phenomena
Czasopismo naukowe
Tytuł:
Biological Evaluation of Antibody-Drug Conjugates Produced by Tag-Free Lipoate Ligase A Modification.
Autorzy:
Yamazaki S; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Ito K; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Aoki T; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Arashida N; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Watanabe T; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Fujii T; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Matsuda Y; Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki 210-8681, Kanagawa, Japan.
Pokaż więcej
Źródło:
Biochemistry [Biochemistry] 2024 Mar 05; Vol. 63 (5), pp. 644-650. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/pharmacology
Antineoplastic Agents*/pharmacology
Rats ; Animals ; Humans ; Ligases ; MCF-7 Cells ; Trastuzumab/pharmacology ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Autorzy:
Daver NG; MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: .
Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain.
DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA.
Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Papadantonakis N; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA.
Todisco E; Istituto Europeo di Oncologia, Milan, Italy.
Sweet KL; Moffitt Cancer Center, Tampa, FL, USA.
Pemmaraju N; MD Anderson Cancer Center, Houston, Texas, USA.
Lane AA; Dana-Farber Cancer Institute, Boston, MA, USA.
Torres-Miñana L; Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Konopleva MY; Albert Einstein College of Medicine, Bronx, NY, USA.
Sloss CM; ImmunoGen, Waltham, MA, USA.
Watkins K; ImmunoGen, Waltham, MA, USA.
Bedse G; ImmunoGen, Waltham, MA, USA.
Du Y; ImmunoGen, Waltham, MA, USA.
Malcolm KE; ImmunoGen, Waltham, MA, USA.
Zweidler-McKay PA; ImmunoGen, Waltham, MA, USA.
Kantarjian HM; MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2024 Mar; Vol. 25 (3), pp. 388-399.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Immunoconjugates*/adverse effects
Leukemia, Myeloid, Acute*/drug therapy
Drug-Related Side Effects and Adverse Reactions*
Hematologic Neoplasms*
Febrile Neutropenia*
Humans ; Female ; Male ; Interleukin-3 Receptor alpha Subunit
Czasopismo naukowe
Tytuł:
Antibody-drug conjugates in acute myeloid leukaemia: more research needed.
Autorzy:
Kayser S; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim 68167, Germany; NCT Trial Centre, National Centre of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2024 Mar; Vol. 25 (3), pp. 272-273.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/adverse effects
Leukemia, Myeloid, Acute*/drug therapy
Humans
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies